Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autonomix Medical, Inc. filings document a development-stage medical device company focused on precision nerve-targeted technology and transvascular approaches to peripheral nerve sensing and treatment. Securities registration statements describe the company’s common stock, warrant instruments, offering mechanics, emerging growth company status, smaller reporting company status, financial statements, convertible note proceeds, and related-party transaction disclosures.
Autonomix’s 8-K filings cover material events including Regulation FD clinical-data disclosures, private placement financing agreements involving pre-funded warrants and Series C warrants, annual meeting voting results, board and auditor matters, reverse stock split authority, and Nasdaq continued-listing compliance notices. These records also reflect capital-structure changes and governance actions tied to the company’s public-company status.
Autonomix Medical director Lori Bisson reported changes to her derivative holdings in a Form 4. The filing discloses transactions involving two option grants with exercise prices of $26.56 and $40, covering 18,862 and 46,680 underlying shares respectively. The $26.56 option was cancelled by mutual agreement and the reporting person received no consideration for that cancellation. Both option amounts were revised to reflect a 1-for-20 reverse stock split. The filing shows direct beneficial ownership following the transactions of 47,930 and 1,250 derivative securities.
Trent N. Smith, identified as the Chief Financial Officer of Autonomix Medical, Inc. (AMIX), reported derivative transactions dated 08/11/2025 involving company stock options. The filing lists an option with a $26.56 exercise price tied to 11,405 underlying shares and an option with a $40.00 exercise price tied to 21,250 underlying shares. The filing’s footnotes state the $26.56 option was cancelled by mutual agreement and that the reporting person received an additional three months' severance as consideration for that cancellation. The footnotes also note the reported share amounts and exercise prices were revised to reflect a 1-for-20 reverse stock split completed on October 25, 2024. Ownership is reported in a direct form.
Autonomix Medical, Inc. is a pre-revenue, clinical-stage medical device company advancing a catheter-based sensing and radiofrequency ablation platform. For the three months ended June 30, 2025, the company reported a net loss of $3.3 million (versus $2.7 million a year earlier), research and development expense of $1.6 million (up 67%), and general and administrative expense of $1.8 million. Cash totaled $8.6 million with working capital of $7.0 million as of June 30, 2025. Weighted average shares outstanding were 3,105,156, producing loss per share of $1.07. The company completed a 1-for-20 reverse stock split and raised financing including a November 2024 offering (gross ~$10.0 million; net proceeds ~$9.0 million) and ATM sales of 1,304,260 shares for net proceeds of ~$2.1 million.
The company reported positive early clinical results from its PoC 1 study with mean pain reduction of 59.2% among responders, no device-related serious adverse events, initiation of PoC 2 in June 2025, two issued U.S. patents, and an FDA pre-submission meeting that framed a path toward an EFS and potential De Novo approval target in 2028. Management discloses substantial doubt about going concern, estimating cash resources sufficient only into, but not beyond, the second calendar quarter of 2026 and forecasting an additional financing need of approximately $32–40 million to reach commercialization.